Sökning: "Factor IX"
Visar resultat 1 - 5 av 29 avhandlingar innehållade orden Factor IX.
- Detta är en avhandling från Hospital Pharmacy, Malmö University Hospital, S-205 02 Malmö, Sweden
Sammanfattning : The aim of the thesis was to increase cost-effectiveness in prophylactic treatment of haemophilia. Prophylaxis is effective to prevent bleedings and arthropathy, but the high cost limits its use. First, a new distribution system for clotting factor concentrates was implemented in Sweden to improve availability and reduce risks and costs. LÄS MER
- Detta är en avhandling från Department of Paediatrics, Lund University
Sammanfattning : Introduction: Haemophilia A (HA) and B (HB) are two of our most common inherited bleeding disorders and are due to a variety of gene mutations. Aims: The overall objective of the present research was to perform clinical and basic scientific studies on haemophilia in Sweden to further improve and individualise the care of haemophilia patients and their relatives. LÄS MER
3. HEMOPHILIA A AND B WITH SPECIAL REFERENCE TO INHIBITOR DEVELOPMENT AND EXPERIMENTAL STUDIES OF FACTORS VIII AND IXDetta är en avhandling från Karin Knobe, Dept. of Pediatrics, University Hospital, Malmö, SE- 20502
Sammanfattning : The general objective of the research underlying this dissertation was to conduct clinical and basic scientific studies to further elucidate the hemophilia and the coagulation process, with the goal of improving the care of families with these disorders. More specific aims were to evaluate epidemiological, genetic, clinical, and biochemical aspects of the development of inhibitors (antibodies) against FVIII and FIX in Swedish patients with hemophilia A and B (papers I, II, and III). LÄS MER
- Detta är en avhandling från Institutionen för kliniska vetenskaper, Lunds universitet
Sammanfattning : Haemophilia is a recessive genetic bleeding disorder in which coagulation time is prolonged due to the absence or malfunction of either of the serum proteins Factor VIII or IX. Joint destruction following repeated haemarthroses is the main cause of morbidity in haemophiliacs, and such arthropathy can be prevented or postponed by implementing prophylactic therapy with factor concentrate at an early age. LÄS MER
- Detta är en avhandling från Mårten Steen, Dept of Clinical Chemistry, University hospital Malmö, 205 02 Malmö
Sammanfattning : The homologous blood coagulation factors V (FV) and factor VIII (FVIII) are important at sites of vascular injury for the amplification of the clotting cascade. Activated FV (FVa) serves as a cofactor to the enzyme activated factor X (FXa) in the activation of prothrombin. This complex is called the prothrombinase complex. LÄS MER